Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery
28. Februar 2023 08:00 ET
|
Olink Proteomics AB
Uppsala, Sweden, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced an agreement with Regeneron Genetics Center® (RGC) focused on the use and development of...
Olink establishes agreement with Regeneron Genetics Center to scale their proteomics efforts, potentially enabling a new era of drug discovery
28. Februar 2023 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced an agreement with Regeneron Genetics Center® (RGC) focused on the use and development of...
Olink reports fourth quarter and full year 2022 financial results
21. Februar 2023 07:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter and full year ended December...
Olink Holding AB (publ) announces pricing of public offering of American Depositary Shares
18. Januar 2023 23:07 ET
|
Olink Proteomics AB
Uppsala, Sweden, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of a public offering of 5,831,028 American Depositary...
Olink Holding AB (publ) launches public offering of American Depositary Shares
18. Januar 2023 16:14 ET
|
Olink Proteomics AB
Uppsala, Sweden, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the launch of a public offering of 5,831,028 American Depositary...
Olink announces preliminary unaudited revenue for the fourth quarter and full year 2022 and provides outlook for 2023
09. Januar 2023 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink” or the “Company”) (Nasdaq: OLK), today announced preliminary unaudited revenue for the fourth quarter and year...
Olink announces preliminary unaudited revenue for the fourth quarter and full year 2022 and provides outlook for 2023
09. Januar 2023 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink” or the “Company”) (Nasdaq: OLK), today announced preliminary unaudited revenue for the fourth quarter and year...
Olink to participate in the 41st Annual JP Morgan Healthcare Conference
29. Dezember 2022 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced its participation in the 41st Annual JP Morgan Healthcare Conference. Company...
Olink to participate in the 41st Annual JP Morgan Healthcare Conference
29. Dezember 2022 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced its participation in the 41st Annual JP Morgan Healthcare Conference. Company...
Maria Martin-Grau, at the University of Valencia, Spain is selected for the 2022 Novelties in Biomarkers award
17. November 2022 08:00 ET
|
Olink Proteomics AB
UPPSALA, Sweden, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) is proud to announce the 2022 winner of the young researchers’ award, Novelties in Biomarkers, Maria...